News

Incruse® Ellipta® (umeclidinium) to be reimbursed in Australia for Chronic Obstructive Pulmonary Disease


TRY IT NOW

Sign up online today & collaborate

or click here to find out more

 Incruse® Ellipta® (umeclidinium) to be reimbursed in Australia for Chronic Obstructive Pulmonary Disease

 

Date:01/12/2014

 

Reimbursed via the Pharmaceutical Benefits Scheme from 1st December 2014 
- Administered using a new dry powder inhaler called Ellipta1


GlaxoSmithKline (GSK) has welcomed the listing of Incruse Ellipta (umeclidinium) on the Australian Pharmaceutical Benefits Scheme (PBS) from December 1st 2014 as a long term once-daily, maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD) which is also known as chronic bronchitis, “smoker’s cough” or emphysema. 

Incruse Ellipta is a once-daily treatment containing umeclidinium, a long-acting muscarinic antagonist (LAMA), delivered by the Ellipta inhaler. 

Australian respiratory specialist and clinical researcher Professor Peter Frith from Repatriation General Hospital said COPD can be a debilitating disease and he welcomed the improved access to new treatments that results from PBS reimbursement. 

“I certainly welcome better access to effective treatment options in COPD that can alleviate symptoms and improve quality of life,” said Professor Frith. 

The PBS listing of Incruse Ellipta will be another key step in the development of GSK’s respiratory portfolio in Australia. It is set to coincide with the listing of Anoro® Ellipta® (umeclidinium/vilanterol) for COPD also on the PBS from 1st December. 

GSK Medical Director, Dr Andrew Weekes says the reimbursement is another crucial step forward in the development of GSK’s respiratory portfolio in Australia. 


For more click here

Source: GSK

© Catalyst Innovation Portal 2019